知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.017 秒)

    SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS
    34.
    发明申请
    SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS 有权

    公开(公告)号：US20210196735A1

    公开(公告)日：2021-07-01

    申请号：US17141772

    申请日：2021-01-05

    申请人： GLYCOM A/S

    发明人： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Emma Elison

    IPC分类号： A61K31/702 ,  A61K9/00 ,  A61K9/20

    摘要： A method includes selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes. The method further includes selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from: fucosylated HMOs 2′-fucosyllactose (2′-FL), 3 -fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), and difucosyllactose (DFL); non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-di sialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and mixtures thereof. The method further includes increasing the relative abundance of Bifidobacterium adolescentis in the non-infant patient by administering the selected effective amount of the selected one or more HMOs and improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation. In various examples, the method includes increasing levels of at least one glucagon-like peptide.

    Synthetic composition for microbiota modulation
    36.
    发明授权
    Synthetic composition for microbiota modulation 有权

    公开(公告)号：US10751354B2

    公开(公告)日：2020-08-25

    申请号：US15759754

    申请日：2016-09-14

    申请人： GLYCOM A/S

    发明人： Louise Kristine Vigsnæs ,  Bruce McConnell

    IPC分类号： A61K31/702 ,  A61P3/04 ,  A61P3/10 ,  A61P1/00 ,  A61K9/00

    摘要： A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of a Bifidobacterium of the B. adolescentis phylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance of B. adolescentis and/or B. pseudocatenulatum; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2′-fucosyllactose (preferred), 2′-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.